bioRxiv ScienceSearch

bioRxiv · 10.1101/390096

Predicting One-Year Outcome in First Episode Psychosis using Machine Learning

Abstract

Lay SummaryO_ST_ABSEvidence before this studyC_ST_ABSOur knowledge of factors which predict outcome in first episode psychosis (FEP) is incomplete. Poor premorbid adjustment, history of developmental disorder, symptom severity at baseline and duration of untreated psychosis are the most replicated predictors of poor clinical, functional, cognitive, and biological outcomes. Yet, such group level differences are not always replicated in individuals, nor can observational results be clearly equated with causation. Advanced machine learning techniques have potential to revolutionise medicine by looking at causation and the prediction of individual patient outcome. Within psychiatry, Koutsouleris et al employed machine learning to predict 4- and 52-week functional outcome in FEP to a 75% and 73.8% test-fold balanced accuracy on repeated nested internal cross-validation. The authors suggest that before employing a machine learning model \"into real-world care, replication is needed in external first episode samples\".\n\nAdded value of this studyWe believe our study to be the first externally validated evidence, in a temporally and geographically independent cohort, for predictive modelling in FEP at an individual patient level. Our results demonstrate the ability to predict both symptom remission and functioning (in employment, education or training (EET)) at one-year. The performance of our EET model was particularly robust, with an ability to accurately predict the one-year EET outcome in more than 85% of patients. Regularised regression results in sparse models which are uniquely interpretable and identify meaningful predictors of recovery including specific individual PANSS items, and social support. This builds on existing studies of group-level differences and the elegant work of Koutsouleris et al.\n\nImplications of all the available evidenceWe have demonstrated the externally validated ability to accurately predict one-year symptomatic and functional status in individual patients with FEP. External validation in a plausibly related temporally and geographically distinct population assesses model transportability to an untested situation rather than simply reproducibility alone. We propose that our results represent important and exciting progress in unlocking the potential of predictive modelling in psychiatric illness. The next step prior to implementation into routine clinical practice would be to establish whether, by the accurate identification of individuals who will have poor outcomes, we can meaningful intervene to improve their prognosis.\n\nAbstractO_ST_ABSBackgroundC_ST_ABSEarly illness course correlates with long-term outcome in psychosis. Accurate prediction could allow more focused intervention. Earlier intervention corresponds to significantly better symptomatic and functional outcomes.\n\nWe use routinely collected baseline demographic and clinical characteristics to predict employment, education or training (EET) status, and symptom remission in patients with first episode psychosis (FEP) at 1 year.\n\nMethods83 FEP patients were recruited from National Health Service (NHS) Glasgow between 2011 and 2014 to a 24-month prospective cohort study with regular assessment of demographic and psychometric measures. An external independent cohort of 79 FEP patients were recruited from NHS Glasgow and Edinburgh during a 12-month study between 2006 and 2009.\n\nElastic net regularised logistic regression models were built to predict binary EET status, period and point remission outcomes at 1 year on 83 Glasgow patients (training dataset). Models were externally validated on an independent dataset of 79 patients from Glasgow and Edinburgh (validation dataset). Only baseline predictors shared across both cohorts were made available for model training and validation.\n\nOutcomesAfter excluding participants with missing outcomes, models were built on the training dataset for EET status, period and point remission outcomes and externally validated on the validation dataset. Models predicted EET status, period and point remission with ROC area under curve (AUC) performances of 0.876 (95%CI: 0.864, 0.887), 0.630 (95%CI: 0.612, 0.647) and 0.652 (95%CI: 0.635, 0.670) respectively. Positive predictors of EET included baseline EET and living with spouse/children. Negative predictors included higher PANSS suspiciousness, hostility and delusions scores. Positive predictors for symptom remission included living with spouse/children, and affective symptoms on the Positive and Negative Syndrome Scale (PANSS). Negative predictors of remission included passive social withdrawal symptoms on PANSS.\n\nInterpretationUsing advanced statistical machine learning techniques, we provide the first externally validated evidence for the ability to predict 1-year EET status and symptom remission in FEP patients.\n\nFundingThe authors acknowledge financial support from NHS Research Scotland, the Chief Scientist Office, the Wellcome Trust, and the Scottish Mental Health Research Network.

Source connections

Explore related subjects

Keep this discovery

BibTeXRIS

Leighton, S. P., Krishnadas, R., Chung, K., Blair, A., Brown, S., Clark, S., Sowerbutts, K., Schwannauer, M., Jonathan, C., Gumley, A.. 2018-08-13. Predicting One-Year Outcome in First Episode Psychosis using Machine Learning. https://doi.org/10.1101/390096

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

The Unreasonable Effectiveness of Cell Types in Describing Neuronal Physiological Features

Single-cell RNA sequencing (scRNA-seq) captures detailed gene expression profiles at scale, while patch-clamp recordings measure intrinsic neuronal electrophysiological properties. Modeling the relations between these two modalities remains a challenge. Here, we compare how well electrophysiological features can be predicted by traditional transcriptomic cell type classification, representations derived from a foundational model (scGPT) pretrained on large-scale scRNA-seq datasets, ion channel-coding genes, and highly variable genes. Using paired transcriptomic and electrophysiological patch-sequencing data from 495 human neurons from neurosurgical tissue, we find that cluster-level cell type representations consistently outperform highly variable gene selection, ion channel gene selection, and context-enriched scGPT embeddings. Notably, performance varies across model architectures and initializations, and the best results are obtained by combining the outputs of separate cell type and scGPT-based models. Together, these findings suggest that traditional discrete cellular classification is highly effective in predicting physiological features. For maximum performance it can be complemented by pretrained transformer models.

neuroscience

A nonlinear inhibition pathway underlying cortical responses to tuned holographic optogenetic perturbations

Optogenetics enables causal manipulation of cortical activity. Perturbation responses can be counterintuitive due to network interactions, making theory essential for predicting them. Existing approaches often rely on linear approximations, which fail for many biologically relevant perturbations. Here we develop a nonlinear theory of responses to holographic perturbations in cell-type-specific recurrent networks with structured connectivity. We fit a nonlinear model to mouse V1 data, which shows cotuned-ensemble suppression: perturbing spatially clustered neurons with similar preferred orientations yields markedly stronger short-range suppression than perturbing untuned ensembles. We show that cotuned-ensemble suppression arises from a feature-tuned, nonlinear inhibition pathway implicating somatostatin-positive (SST) interneurons. The theory predicts that cotuned ensembles suppress parvalbumin-positive (PV) neurons but facilitate SST neurons, and links the degree of cotuned-ensemble suppression or facilitation to the variance of the SST response. This framework identifies mechanisms by which nonlinear inhibition sculpts cortical dynamics and establishes a predictive basis for targeted optogenetic interventions.

neuroscience

Proteomic signatures of APOE ε4 across human tissues and cell types in Alzheimers disease

The apolipoprotein E {varepsilon}4 (APOE {varepsilon}4) allele is the strongest genetic risk factor for late-onset Alzheimers disease (AD). However, the underlying molecular mechanisms remain unclear. This study included 1691 participants from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP), 1226 participants from the Accelerating Medicines Partnership - Alzheimers Disease (AMP-AD) Diverse Cohorts Study, and 735 participants from the Alzheimers Disease Neuroimaging Initiative (ADNI). To characterise APOE {varepsilon}4 molecular effects, we analysed proteomic data from plasma, cerebrospinal fluid (CSF), and induced pluripotent stem cell (iPSC)-derived astrocytes and neurons, as well as transcriptomic and proteomic data from multiple brain regions. The association of APOE {varepsilon}4 with AD neuropathology was also examined. APOE {varepsilon}4 carriers shared a plasma proteomic signature enriched for immune processes, irrespective of AD diagnosis. A machine learning classifier trained on this signature discriminated APOE {varepsilon}4 carriers from non-carriers in an independent cohort using CSF proteomics. APOE {varepsilon}4 carriage was associated with higher Braak stages and Consortium to Establish a Registry for Alzheimers Disease (CERAD) score. However, only limited APOE {varepsilon}4-associated transcriptomic and proteomic changes were observed in bulk brain tissue, with poor cross-layer concordance. Proteomic analyses of iPSC-derived astrocytes and neurons further revealed cell-type-specific APOE {varepsilon}4-associated changes. APOE {varepsilon}4 is associated with a consistent proteomic signature across plasma and CSF. Its molecular effects in the brain differ across cell types, brain regions and molecular layers. These findings support the need for cell-type-resolved multi-omic studies to elucidate how APOE {varepsilon}4 confers AD risk.

neuroscience